Acute Decompensated Heart Failure & Cardiorenal Syndrome
Sort by warm/cold and wet/dry, then decongest without fearing the creatinine
Overview and the bedside profile
Definition. Acute decompensated heart failure (ADHF) is a new or rapidly worsening set of HF symptoms and signs that needs urgent, usually inpatient, therapy. Most patients present with congestion rather than low output, and the same framework applies to reduced and preserved ejection fraction.
Two bedside questions. Is the patient wet — orthopnea, JVD, hepatojugular reflux, rales, edema, S3, ascites? Is the patient cold — cool or mottled extremities, narrow pulse pressure, confusion, oliguria, rising lactate or creatinine, symptomatic hypotension? A proportional pulse pressure (pulse pressure ÷ systolic BP) below 25% suggests a cardiac index under 2.2 L/min/m².
Invasive correlates. In the Forrester scheme, wet corresponds to a PCWP above 18 mmHg and cold to a cardiac index below 2.2 L/min/m². A pulmonary artery catheter is not routine; use it when volume or perfusion status is unclear, symptoms are refractory, or shock and advanced therapies are being considered.
| Profile | Findings | First-line approach |
|---|---|---|
| Warm-wet (most common) | Congestion, adequate perfusion | IV loop diuretic ± nitroglycerin; continue GDMT |
| Cold-wet | Congestion plus hypoperfusion | Dobutamine or milrinone ± norepinephrine, then diuresis; hold beta-blocker; mechanical support if refractory |
| Cold-dry | Hypoperfusion without congestion | Hold diuretics and vasodilators; cautious fluid if underfilled; inotrope if output stays low |
| Warm-dry | Compensated | Optimize oral GDMT; look for another cause of symptoms |
Diagnostic workup and precipitants
Natriuretic peptides. BNP below 100 pg/mL or NT-proBNP below 300 pg/mL makes acute HF unlikely. BNP runs falsely low in obesity and high with CKD, older age, and sacubitril-valsartan; because neprilysin inhibition raises BNP itself, follow NT-proBNP in patients taking an ARNI.
Imaging and ECG. The chest film shows cephalization, Kerley B lines, interstitial then bat-wing alveolar edema, and pleural effusions; lung ultrasound shows diffuse B-lines. Echocardiography defines EF, valves, and wall motion. ECG and troponin look for ischemia or arrhythmia as the trigger, and CBC, BMP, TSH, and liver tests complete the baseline.
Precipitants. Decompensation almost always has a trigger worth finding:
- Dietary sodium or medication nonadherence — among the most common and most preventable
- Ischemia or ACS; new AF or another tachy- or bradyarrhythmia
- Uncontrolled hypertension; infection, especially pneumonia
- Anemia, hyper- or hypothyroidism, pulmonary embolism, alcohol, worsening renal function, pregnancy
- Drugs: NSAIDs (sodium retention, blunted diuretic response), thiazolidinediones such as pioglitazone (fluid retention; avoid in NYHA III–IV), non-dihydropyridine CCBs (verapamil, diltiazem: negative inotropy in HFrEF), corticosteroids, and excess IV fluid
Treating congestion
Loop diuretics. Give IV furosemide promptly at a total daily dose about 1–2.5 times the oral home dose (diuretic-naive: 20–40 mg IV). Bolus and continuous infusion are equivalent, and higher doses decongest faster with only transient creatinine changes. Oral furosemide is only about 50% bioavailable, and gut edema reduces absorption further.
Monitoring response. Track strict intake and output, daily weights, and daily electrolytes and creatinine. A spot urine sodium below 50–70 mEq/L about 2 hours after a dose, or low hourly urine output in the first hours, flags an inadequate response.
- Double the loop doseIV, as soon as the response is inadequate.
- Add a thiazide-type diureticMetolazone 2.5–5 mg PO or IV chlorothiazide: sequential nephron blockade of the distal convoluted tubule, which hypertrophies and reclaims sodium after chronic loop use.
- Watch the chemistryHypokalemia, hypomagnesemia, hyponatremia, and overdiuresis.
- Other agentsAcetazolamide can augment natriuresis; SGLT2 inhibitors add mild diuresis.
- Refractory congestionUltrafiltration (not better than stepped diuretic therapy as routine care) or inotropes when low output is the problem.
Vasodilators. IV nitroglycerin speeds dyspnea relief when systolic BP is adequate (roughly above 100–110 mmHg): venodilation at low doses lowers preload and arteriolar dilation at higher doses lowers afterload. Nitroprusside is a potent balanced vasodilator for severe hypertension or acute severe mitral or aortic regurgitation; prolonged use, especially with renal failure, risks cyanide or thiocyanate toxicity.
Avoid nitrates with hypotension, RV infarction, severe aortic stenosis, or a recent PDE-5 inhibitor (sildenafil within 24 hours, tadalafil within 48 hours).
Oxygen and ventilation. Sit the patient upright to reduce venous return, and give oxygen only when SpO2 is below 90%. CPAP or BiPAP for respiratory distress lowers preload and afterload, reduces the work of breathing, and cuts intubation; intubate for altered mental status, inability to protect the airway, or NIV failure. Routine morphine is no longer advised because it has been linked to more mechanical ventilation and worse outcomes.
Low-output states: cold-wet and cold-dry
Cold-wet. Perfusion comes first: an inotrope, plus norepinephrine for hypotension, then diuresis once perfusion improves. Refractory cardiogenic shock calls for mechanical circulatory support (intra-aortic balloon pump, Impella, VA-ECMO) and evaluation for advanced therapies. Inotropes are a short-term bridge; chronic use increases arrhythmias and mortality.
| Drug | Mechanism | Best use | Cautions |
|---|---|---|---|
| Dobutamine | β1 agonist → ↑contractility | Cold-wet with adequate BP | Tachyarrhythmias; blunted by beta-blockers |
| Milrinone | PDE-3 inhibitor → ↑cAMP; inotropy plus vasodilation | Cold-wet, especially on beta-blockers | Hypotension; renally cleared, so reduce in CKD |
| Norepinephrine | α1 and β1 agonist | Hypotension or cardiogenic shock | Raises afterload; pair with an inotrope |
| Nitroglycerin | Venodilator, arterial dilator at higher doses | Warm-wet, flash pulmonary edema | Hypotension; PDE-5 inhibitors |
Beta-blockers. Continue them in warm-wet decompensation, since withdrawal is associated with higher mortality; halve the dose if BP or perfusion is borderline. Hold them in cardiogenic shock or cold-wet low output, symptomatic bradycardia, or high-grade AV block. Start a new beta-blocker only when the patient is euvolemic and off IV diuretics, vasodilators, and inotropes.
Cold-dry. Low output without congestion, often from overdiuresis or advanced HF. Hold diuretics and vasodilators, give cautious fluid if filling pressures are low, and use an inotrope if output stays low. Persistent low output points to advanced (stage D) HF: evaluate for LVAD, transplant, or palliative inotropes.
Flash pulmonary edema and cardiorenal syndrome
Flash pulmonary edema. Abrupt alveolar flooding, usually with severe hypertension and a sympathetic surge ("sympathetic crashing" acute pulmonary edema), often with preserved EF. The afterload spike raises LV filling and left atrial pressure, so fluid redistributes into the lungs rather than accumulating in the body. Treat with upright positioning, BiPAP, and high-dose nitroglycerin — large sublingual or IV boluses followed by an infusion; diuretics are secondary.
Look for a cause. Consider acute ischemia with papillary muscle dysfunction (acute MR), severe aortic stenosis, and hypertensive emergency. When episodes recur with preserved EF, resistant hypertension, and a creatinine jump after an ACE inhibitor or ARB, suspect bilateral renal artery stenosis (Pickering syndrome): screen with renal duplex, CTA, or MRA. Recurrent flash pulmonary edema is an accepted indication for renal artery stenting.
Cardiorenal syndrome type 1. Acute cardiac dysfunction causing AKI. Renal venous congestion from high central venous pressure is the dominant mechanism, with low cardiac output and neurohormonal activation contributing.
A modest creatinine rise while the patient is still congested and diuresing well is acceptable — keep decongesting. Residual congestion at discharge predicts readmission and death more strongly than the creatinine, and hemoconcentration during diuresis signals effective decongestion.
When kidneys worsen and congestion persists. Reassess for low output (consider inotropes), hypotension, nephrotoxins such as NSAIDs or contrast, and urinary obstruction. Low-dose "renal" dopamine does not improve decongestion or renal function, and ultrafiltration is reserved for refractory congestion.
GDMT in hospital and the transition home
Continue GDMT. Keep ACE inhibitor, ARB, or ARNI, the MRA, and the beta-blocker unless hypotension, shock, hyperkalemia, or significant AKI forces a hold.
Start before discharge. Once stable, begin or up-titrate the four HFrEF pillars: a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), an ARNI (or ACE inhibitor/ARB), an MRA, and an SGLT2 inhibitor (dapagliflozin or empagliflozin). SGLT2 inhibitors also reduce HF events in HFpEF. Digoxin (symptom relief only) and ivabradine (sinus rhythm with HR ≥70 on a maximal beta-blocker) are add-ons, not substitutes, and non-dihydropyridine CCBs are harmful in HFrEF.
- Euvolemic on a stable oral diuretic regimen
- Sodium and fluid education and medication reconciliation
- Daily morning weights; call for a gain above 2–3 lb in a day or 5 lb in a week
- Follow-up visit within 7 days for labs, volume check, and GDMT titration